| 耐碳青霉烯肠杆菌科细菌的流行病学特点以及抗生素应用策略 |
| |
| 引用本文： | 张露方,耿荣华,曲芬.耐碳青霉烯肠杆菌科细菌的流行病学特点以及抗生素应用策略[J].中国抗生素杂志,2019,44(9):1008-1014. |
| |
| 作者姓名： | 张露方 耿荣华 曲芬 |
| |
| 作者单位： | 航空总医院检验科 |
| |
| 基金项目： | 医院多重耐药研究课题(No.TB209-020) |
| |
| 摘 要： | 耐碳青霉烯肠杆菌科细菌(carbapenem-resistant Enterobacteriaceae,CRE)在全球范围内的快速增长和流行,直接影响临床治疗与患者预后,并给社会经济带来了严重负担。目前CRE临床治疗可供选择的药物有黏菌素、氨基糖苷类、替加环素和磷霉素等;美国食品药品监督局(FDA)批准的新药即头孢他啶/阿维巴坦(ceftazidime/avibactam,CAZ-AVI)、美罗培南/瓦博巴坦(meropenem/vaborbactam,MER-VAB)、亚胺培南/雷巴坦(imipenan/ribatan,AMI-LEI)和plazomicin也为CRE感染治疗提供了新的选择,但各类药物的治疗效果、新的耐药产生及不良反应各有不同,为优化临床治疗方案,提高治疗效果,本文对CRE的治疗药物的现状做一分析。
|
| 关 键 词： | 碳青霉烯酶 肠杆菌科细菌 流行 耐药 治疗 |
Epidemiology and treatment strategies for carbapenem-resistant Enterobacteriaceae |
| |
| Zhang Lu-fang,Geng Rong-hua,Qu Fen.Epidemiology and treatment strategies for carbapenem-resistant Enterobacteriaceae[J].Chinese Journal of Antibiotics,2019,44(9):1008-1014. |
| |
| Authors: | Zhang Lu-fang Geng Rong-hua Qu Fen |
| |
| Institution: | (Department of Laboratory,Aviation General Hospital,Beijing 100012) |
| |
| Abstract: | Carbapenem-resistant Enterobacteriaceae (CRE) spreads worldwide, which results in susceptibility and extremely high mortality, and becomes a major public health threat in the world. So far, some antibiotics, colistin, aminoglycosides, tegacycline, and fosfomycin, applied in clinic, are available for CRE. Besides, new drugs which have been approved by United States Food and Drug Administration (FDA) , such as ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MER-VAB), amipenan-Leibatan (AMI-LEI), and plazomicin, offer options for CRE. However, application of these drugs is seriously limited by the rapid resistance of pathogenic bacteria. In the article, the authors reviewed the epidemiology and treatment strategies of CRE to provide correct information to the |
| |
| Keywords: | Carbapenemase Enterobacteriaceae bacteria Epidemiology Drug resistance Treatment |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中国抗生素杂志》浏览原始摘要信息 |
| 点击此处可从《中国抗生素杂志》下载免费的PDF全文 |
|
